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ABSTRACT 
Objective: Rheumatoid arthritis is a common autoimmune disease for which there is no known 
cure. Ultraviolet light can induce immunosuppressive effects. Our main objective was to 
ascertain whether a complementary treatment with phototherapy improves changes in functional 
scales in patients with rheumatoid arthritis.  
 
Methods: Seven women with rheumatoid arthritis were enrolled for this study and submitted to 
phototherapy sessions with a 425 to 650 nm lamp.  
 
Results: The Karnofsky scale changed from requiring frequent medical care to being capable of 
normal activity with few symptoms or signs of disease (p = 0.018), the RaQol questionnaire 
decreased abruptly from 29 to zero points (p = 0.018), the Steinbrocker Functional Capacity 
Rating changed from limited to little or none of the duties of usual occupation or self-care to 
complete ability to carry out all the usual duties without handicaps (p = 0.017). The pain was 
remitted after the treatment period. The acute inflammation variables showed a significant 
decrease after the indicated sessions, C-reactive protein (p = 0.042), erythrocyte sedimentation 
rate (p = 0.018).  
 
Conclusion: The evaluated scales clearly show a benefit with the phototherapy in rheumatoid 
arthritis patients. Thus, phototherapy seems to be a plausible complementary option to reduce the 
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Rheumatoid arthritis (RA) is a common autoimmune disease for which there is no known cure.      
A diverse number of biological pathways are altered in patients with RA, which impinge on a 
wide-variety of cell types, tissue types and organ systems – innate immune cells (eg dendritic 
cells, mast cells, neutrophils, platelets), adaptive immune cells (eg B and T-cells), bone, cartilage, 
synovial fibroblasts, vascular cells, brain, muscle and fat (1). The chronic manifestations of RA 
are primarily manifested in the synovial tissues, with symptoms of pain, stiffness, swelling, and 
progressive joint destruction (2).  
Drugs used for treatment can be divided into four broad categories: non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids, disease modifying antirheumatic drugs 
(DMARDs) and biologic agents. Since 2002, treatment recommendations for RA have suggested 
an aggressive approach to inhibit the progression of joint damage and other complications that 
may develop soon after diagnosis (3‒5). This aggressive approach includes initiation of 
DMARDs and biologic agents as soon as possible. 
Among complementary alternatives to treat RA we find the use of light. In this respect, 
the frequency, wavelength and energy of an electromagnetic wave are related to one another with 
wavelength being inversely proportional to both frequency and energy. The huge spectrum of 
electromagnetic radiation can therefore be organized conceptually by decreasing wavelength into 
radio waves, microwaves, terahertz radiation, infrared radiation, visible light, ultraviolet (UV) 
radiation, X-rays and gamma rays.  
Phototherapy is defined as the use of UV radiation in the treatment of skin disease. There 
are many types of phototherapy including: broadband UVB (280–320 nm), narrowband UVB 
(311‒313 nm), UVA (340–400 nm), and combination therapy of psoralen plus UVA (PUVA). 




Although UV light can induce strong inflammatory responses in susceptible individuals, under 
chronic or minimally erythematogenic doses its immunosuppressive effects are dominant.               
The mechanism of this immunosuppression involves both cellular components and soluble 
mediators (6). For example, Langerhans cells are very sensitive to UV radiation. These cells 
express molecules such as: MHC class II, lymphocyte function-associated antigen-3 (LFA-3), 
intercellular adhesion molecule (ICAM)-1, ICAM-3, B7, CD1a and CD40. Ultraviolet radiation 
induces these cells to migrate out of the skin to draining lymph nodes (7‒8) and there is a 
dramatic reduction in the previously mentioned markers following UV exposure (9).  
Our main objective was to evaluate the changes in functional scales, biochemical and 
inflammatory variables in RA patients submitted to phototherapy within a range from 425 to 650 




In this descriptive, prospective, longitudinal and quasi-experimental clinical study, women 
attending the Research Department of the Maternal-Perinatal Hospital “Mónica Pretelini Sáenz” 
(HMPMPS), Health Institute of the State of Mexico (ISEM), Toluca, State of Mexico, Mexico, 
who meet the criteria established by the American College of Rheumatology (10) for the 
diagnosis of RA were included in the study. Patients with previous fractures, chronic diseases 
that limit the functional capacity, other arthropathies or overlap syndromes were not included.  
An essential aspect of the study was the absolute respect to the management, evaluation 
and subsequent citations instituted by the treating rheumatologist. Only in cases where the patient 
was not receiving specialized care or that their problem was recently installed and did not have 




opportunity to apply this specialized care, we initiated the pharmacological management in 
conjunction with phototherapy. 
We obtained the general personal data from a medical history; anthropometry, 
biochemical evaluations and clinical scales to evaluate the RA affection were evaluated weekly. 
Anthropometric measures were assessed in the Research Laboratory of the HMPMPS. 
Body weight was measured in an overnight fasting status without shoes in a minimal clothing 
state by the use of a digital scale (Seca, Hamburg, Germany) to the nearest 0.1 kg. Height was 
measured using a non-stretched tape measure to the nearest 0.1 cm. Body mass index (BMI) was 
calculated as weight in kg divided by height in meters squared. 
We applied the next clinical evaluations: Karnofsky scale, quality of life-rheumatoid 
arthritis (QOL-RA), rheumatoid arthritis-specific quality of life (RAQoL) instrument, 
steinbrocker functional capacity rating and the visual analog scale (VAS). Also, we evaluated the 
next items: spontaneous pain, pressure pain, movement pain and inflammation (flogosis) with the 
next parameters: 0 (absent), + (light), ++ (moderate), +++ (sever); functional limitation and 
temperature rise were classified as: 0 (absent), 1 (present); strength (excluding hands) was 
evaluated as: 1 (normal), - 1 (diminished), - 2 (very diminished).  
Fasting blood samples (10 mL) were taken at the HMPMPS laboratory in an early 
morning after an overnight fast. Serum samples were analysed for serum total proteins, albumin, 
globulin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate 
dehydrogenase (LDH), bilirrubins, creatinine, blood urea nitrogen (BUN), urea, uric acid 
(Dimension Rx L Max, Dade Behring, USA), hemogram (Advia 120, Bayer Health, USA), 
fasting plasma glucose [FPG] (Dimension Rx L Max, Dade Behring, USA), erythrocyte 
sedimentation rate (ESR), creatine phosphokinase (CPK), electrolytes (Na, K, Ca, P, Mg, Cl), 




venereal disease research laboratory (VDRL), C-reactive protein (CRP), rheumatoid factor (RF), 
urine test and cyclic citrullinated antibody test (Ac-antiCCP). All these tests were measured 
according to standardized procedures recommended by the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC). 
The phototherapy lamp developed by our research team (Federal Ministry of Health 
registration number: 1694E95), uses the electromagnetic spectrum within a range from 425 to 
650 nm (visible light spectrum), 11.33 Joules/cm2. With the patient in supine position, after 
registering vital signs (blood pressure, heart rate, respiratory rate and temperature), weight, height 
and capillary glucose determination, we proceeded to place the phototherapy device 30 cm above 
the chest. 
The phototherapy scheme was: a) 45 minute daily sessions from Monday to Friday for              
2 to 3 months, b) 3 sessions per week of 45 min for 1 to 2 months, c) Twice a week sessions of 
45 min for 1 to 2 months, d) A weekly session for 1‒2 months until completion. Weekly 
frequency and progressive reduction of the phototherapy sessions were determined according to 
the patients’ own improvement.  
The protocol was approved by the Research Committee of the HMPMPS (November 
2010). We followed the Helsinki Declaration, Fortaleza, Brazil and all patients were asked to sign 
the written informed consent.  
Statistical analysis was performed using SPSS version 19. First, descriptive analyses were 
performed and then we compared if the group presented differences through the time by 
Wilcoxon test. Difference was considered significant at p ≤ 0.05.  
 
 





A total of seven patients, all women, media age of 44 years (range 21‒56), with RA were 
enrolled for this study. Four patients were already in treatment with a Rheumatologist, and three 
were naïve to any kind of treatment.  
The media of antirheumatic drugs that patients were taking at the moment of starting the 
protocol was of 2.2. The media of time within the protocol was of 140 ± 7.7 (SE) days and the 
media of prescribed phototherapy sessions was of 66 [range 34‒77] (Table 1).  
 
Table 1. General characteristics of the patients 
Variable Patient 
1 2 3 4 5 6 7 
Age (years) 21 49 41 34 56 46 44 
Familial cases of RA 0 0 0 1 0 0 5 










Occupation Student Worker Worker Dentist Home Home Worker 
Disease  duration 
(months) 
4 56 43 80 73 39 116 

























Co-morbidities  Obesity 
HT 





Cl: cloroquine, Dc: diclofenac, HC: hypercholesterolemia, Hcq: hydroxychloroquine. HT: hypertriglyceridemia,                            
Mtx: methotrexate, Pc: paracetamol, Pred: prednisone, Pxc: piroxicam, RA: rheumatoid arthirtis, RtD: delayed action 
diclofenac, Sz: sulfasalazine 
 




The clinical characteristics of the studied women are showed in Table 2.  
 
Table 2. Anthropometric and clinical characteristics 
Variable Initial Final p 
Spontaneous pain 6 ± 2.9 0 ± 0.14 0.028 
Movement pain 25 ± 4.3 0 0.018 
Pressure pain 32 ± 4.8 0 ± 0.72 0.018 
Inflammation 4 ± 1.6 0 ± 0.56 0.028 
Affected joints 35 ± 1.6 0 ± 1.5 0.018 
Deformed joints 0 ± 1.5 0 ± 1.5  
Functional limitation 10 ± 1.9 0 ± 0.14 0.018 
CRP (mg/L) 80 ± 19.5 0 ± 29.5 0.042 
ESR (mm/min) 40 ± 6 26 ± 3.9 0.018 
RF (IU) 80 ± 172 0 ± 29.5  
Total proteins (mg/dL) 7.8 ± 0.23 7.6 ± 0.25  
Albumin (mg/dL) 3.7 ± 0.13 3.9 ± 0 0.018 
Globulins (mg/dL) 4 ± 0.27 3.6 ± 0.23  
Cholesterol (mg/dL) 188 ± 11 177 ± 13 0.018 
Triglycerides (mg/dL) 104 ± 15 108 ± 6  
 
CRP: C reactive protein, ESR: erythrocyte sedimentation rate, RF: rheumatoid factor. 
 
 




Table 3 shows the results of the evaluated scales.   
Table 3. Scales of evaluation 
Scale Initial Final p 
Karnofsky 50 ± 4.7 90 ± 2.6 0.018 
QOL-RA 12 ± 2.6 77 ± 1.8 0.028 
RaQol 29 ± 0.75 0 ± 1.1 0.018 
Steinbrocker functional classification 3 ± 0.21 1 ± 0.14 0.017 
VAS 9 ± 0.6 0 ± 0.4 0.018 
 
QOL-RA: quality of life-rheumatoid arthritis scale, RAQoL: rheumatoid arthritis-specific quality of life,  
VAS: visual analogue scale. 
 
 
All the median scores were significantly better rated after the treatment period. Karnofsky 
changed from requiring frequent medical care to being capable of normal activity with few 
symptoms or signs of disease. The RaQol questionnaire decreased abruptly from 29 to cero 
points. Steinbrocker Functional Capacity Rating changed from limited to little or none of the 
duties of usual occupation or self-care to complete ability to carry out all the usual duties without 
handicaps. The pain was remitted after the treatment period. 
The acute inflammation variables declined notoriously after the indicated sessions. 
Erythrocyte sedimentation rate diminished more significantly than CRP although both reached a 









There are many research lines searching for a better prognosis in RA. In spite of the great 
advances with the biological drugs, there is not still a cure and the cost of such therapy is not 
easily affordable for most of the patients. In this line of explorative options, there is scarce 
information related to the RA treatment with light exposure. In this respect, the described 
techniques are extracorporeal photochemotherapy (EPC), photodynamic therapy (PDT), 
photopheresis and UVA. 
Extracorporeal photochemotherapy has been applied in refractory RA with clinical 
improvement, a decline in CRP and no adverse reactions recorded (11). Photodynamic therapy is 
based on the use of light-sensitive molecules called photosensitizers. This photoactivation causes 
the formation of singlet oxygen, which produces peroxidative reactions that can cause cell 
damage and death (12).  
The use of photosensitizers is not a new topic in medicine (13). Experimentally, 
incubation with chloroquine or methotrexate and subsequent laser irradiation at a wavelength of 
351 nm resulted in an at least twenty-fold enhanced cytotoxicity. Both substances therefore may 
serve for a photodynamic therapy of rheumatoid arthritis (14). We can not exclude the possibility 
of some patients being beneficiated under a photodynamic effect of either of both drugs. 
Ultraviolet light may be effective in the treatment of patients with RA, but elucidation of 
its precise role requires further study including double-blind trials (15). Photopheresis is an 
extracorporeal form of photochemotherapy with 8-methoxypsoralen (8-MOP) and UVA 
radiation. This therapeutic option leads to the induction of antigen-specific immune suppression 
directed to the pathogenic clone of T-cells (16). In 1991, Malawista et al conducted a study in                
seven patients with RA who were treated with extracorporeal photopheresis. After a treatment 




period between 12 and 16 weeks positive responses were obtained in four of seven patients, 
noting a decrease in number and degree of joint involvement and in morning stiffness and pain 
(17). 
Our approach differs in many senses in relation to the above mentioned works. First, we 
used visible wavelength, which, to our knowledge is the first study demonstrating a clinical 
benefit in RA. In evaluating the clinical benefits with any treatment in RA patients the use of 
functional scales is mandatory. Our group has evaluated not one but five scales, all of them with 
evident demonstration of the successful in managing RA patients with phototherapy.  
As it is well known, an objective way to probe the benefit of any treatment is the 
decreased in inflammatory variables. Our results showed a decrease in CRP and ESR. As an 
initial attempt we did not quantify TNF-α expression that has been included in a new protocol 
that has already begun. 
A critical point to be considered is the role of vitamin D as its shortage in the diet added 
to a low sun light exposure could predispose to several diseases including RA (18). In this 
respect, the fact that we use the 425 to 650 nm wavelength, could stimulate the vitamin D 
synthesis and as a consequence get a clinical benefit derived from this vitamin pathway. Whether 
phototherapy induces a clinical improvement by reducing oxidative stress, changing 
isomerization or any other molecular effect was beyond the scope of the present study. 
This study has its limitations. The low number of cases does not give us enough power to 
extrapolate the results to a more diverse population. Also, it was not a randomized clinical trial as 
it was impossible to enroll enough naïve RA patients and successfully integrate comparative 
groups. This last attempt has to be developed in a Hospital with considerable RA incidence. 




Despite the above mentioned limitation, our study has a strong point in reporting the results of 
five clinical scales and not only one. 
Another point to be considered is the placebo effect. Without any doubt, this effect 
contributes to a feel of welfare but it would not be as definitely as has been documented using 
five different clinical scales. Moreover the placebo effect is conditioned by the personality (19), 
being extremely difficult that the seven patients had the same factors influencing placebo 
response. Finally, the mechanism that underlies the phototherapy has yet to be elucidated 
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